Wave Life Sciences Ltd. (WVE)
| Market Cap | 307.21M |
| Revenue (ttm) | 20.08M |
| Net Income (ttm) | -149.91M |
| Shares Out | 49.00M |
| EPS (ttm) | -3.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $6.27 |
| Previous Close | $6.34 |
| Change ($) | -0.07 |
| Change (%) | -1.10% |
| Day's Open | 6.40 |
| Day's Range | 6.10 - 6.53 |
| Day's Volume | 334,179 |
| 52-Week Range | 4.82 - 19.98 |
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
No one ever said drug development was easy.
Wave Life Sciences Ltd's (NASDAQ: WVE) closely-watched antisense oligonucleotide program crashed in an early-stage Huntington's disease study, thus wiping out two experimental drug candidates. What Happ...
mHTT results from PRECISION-HD trials do not support further development of WVE-120102 and WVE-120101
Investors need to pay close attention to Wave Life Sciences (WVE) stock based on the movements in the options market lately.
CAMBRIDGE, Mass., March 19, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battlin...
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -7.27% and -30.61%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of WAVE Life Sciences (NASDAQ:WVE) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share were up 64.24% year over year to ($0.59), which beat the estimat...
Strong execution in 2020 sets stage for advancing five clinical programs and novel ADAR editing modality in 2021
CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling...
Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling...
Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q3 2020 Results - Earnings Call Transcript
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -17.81% and -76.49%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Results from all cohorts of PRECISION-HD1 and PRECISION-HD2 clinical trials and initial OLE data on track for 1Q 2021
Wave Life Sciences (WVE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling...
CAMBRIDGE, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battl...
CAMBRIDGE, Mass., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battl...
Investors liked an analyst's upgrade of the biotech stock.
CAMBRIDGE, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battl...
Investors need to pay close attention to Wave Life Sciences (WVE) stock based on the movements in the options market lately.
CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battl...
CAMBRIDGE, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battl...
Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q2 2020 Results - Earnings Call Transcript
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -11.65% and -57.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of WAVE Life Sciences (NASDAQ:WVE) moved higher by 1% in pre-market trading after the company reported Q2 results.
Data from 32 mg cohorts of both PRECISION-HD trials and PRECISION-HD OLE trials expected in 1Q 2021
Neurology pipeline discussion will include new preclinical data for C9orf72 program for ALS and FTD
Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battli...
Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors need to pay close attention to Wave Life Sciences (WVE) stock based on the movements in the options market lately.
Newly created position will focus on translating advancements from PRISM platform into new therapeutic candidates Newly created position will focus on translating advancements from PRISM platform into n...
Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q1 2020 Results - Earnings Call Transcript
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -2.99% and -42.72%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of WAVE Life Sciences (NASDAQ:WVE) were unchanged at $7.97 after the company reported Q1 results.
Data from both PRECISION-HD clinical trials expected in 2H 2020
Wave Life Sciences Ltd. (WVE) CEO Dr.
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -11.49% and -57.39%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wave Life Sciences Ltd. (WVE) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Wave Life Sciences (WVE) news for Monday has WVE stock taking a beating on early data from its Huntington’s disease trial. The post Wave Life Sciences News: WVE Stock Crashes 50% on Huntington’s Disease...
Wave Life Sciences Ltd. (NASDAQ: WVE) shares dropped sharply to start out the week after the company announced topline data from its ongoing midstage trial in Huntington’s disease.
Wave Life Sciences stock collapsed Monday after the biotech company's experimental Huntington's disease treatment underperformed a rival drug from Roche and Ionis Pharmaceuticals. The post Why This Bio...
Wipeout In Wave Life Sciences
WVE-120102 demonstrates statistically significant reduction in disease-causing mutant HTT protein in CSF vs. placebo
Investors need to pay close attention to Wave Life Sciences (WVE) stock based on the movements in the options market lately.
Wave Life Sciences (WVE) news for Monday about it giving up on a Duchenne muscular dystrophy drug is hitting WVE stock hard. The post Wave Life Sciences News: WVE Stock Slammed 54% by Duchenne Drug Fail...
About WVE
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It develops WVE-120101 and WVE-120102, a stereopure therapeutic candidates, which are in Phase 1b/2a clinical trials f... [Read more...]
| Industry Biotechnology | IPO Date Nov 11, 2015 |
| CEO Paul Bolno | Employees 217 |
| Stock Exchange NASDAQ | Ticker Symbol WVE |
Financial Performance
In 2020, WVE's revenue was $20.08 million, an increase of 25.61% compared to the previous year's $15.98 million. Losses were -$149.91 million, -22.58% less than in 2019.
Analyst Forecasts
According to 8 analysts, the average rating for WVE stock is "Buy." The 12-month stock price forecast is 9.14, which is an increase of 45.77% from the latest price.